Bergenbio ASA (BGBIO) - Net Assets
Based on the latest financial reports, Bergenbio ASA (BGBIO) has net assets worth Nkr67.00 Million NOK (≈ $7.05 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr86.75 Million ≈ $9.13 Million USD) and total liabilities (Nkr19.75 Million ≈ $2.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bergenbio ASA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr67.00 Million |
| % of Total Assets | 77.24% |
| Annual Growth Rate | 23.49% |
| 5-Year Change | -81.69% |
| 10-Year Change | 89.51% |
| Growth Volatility | 312.27 |
Bergenbio ASA - Net Assets Trend (2013–2024)
This chart illustrates how Bergenbio ASA's net assets have evolved over time, based on quarterly financial data. Also explore Bergenbio ASA assets under control for the complete picture of this company's asset base.
Annual Net Assets for Bergenbio ASA (2013–2024)
The table below shows the annual net assets of Bergenbio ASA from 2013 to 2024. For live valuation and market cap data, see Bergenbio ASA stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr122.70 Million ≈ $12.91 Million |
-3.75% |
| 2023-12-31 | Nkr127.48 Million ≈ $13.41 Million |
+44.04% |
| 2022-12-31 | Nkr88.50 Million ≈ $9.31 Million |
-76.98% |
| 2021-12-31 | Nkr384.43 Million ≈ $40.45 Million |
-42.64% |
| 2020-12-31 | Nkr670.23 Million ≈ $70.53 Million |
+204.99% |
| 2019-12-31 | Nkr219.75 Million ≈ $23.12 Million |
-34.85% |
| 2018-12-31 | Nkr337.28 Million ≈ $35.49 Million |
-3.73% |
| 2017-12-31 | Nkr350.35 Million ≈ $36.87 Million |
+128.58% |
| 2016-12-31 | Nkr153.27 Million ≈ $16.13 Million |
+136.72% |
| 2015-12-31 | Nkr64.75 Million ≈ $6.81 Million |
-54.20% |
| 2014-12-31 | Nkr141.38 Million ≈ $14.88 Million |
+1073.58% |
| 2013-12-31 | Nkr12.05 Million ≈ $1.27 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bergenbio ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2201900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr22.02 Million | 17.95% |
| Common Stock | Nkr39.09 Million | 31.86% |
| Other Components | Nkr61.60 Million | 50.20% |
| Total Equity | Nkr122.70 Million | 100.00% |
Bergenbio ASA Competitors by Market Cap
The table below lists competitors of Bergenbio ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AHT Syngas Technology NV
F:3SQ1
|
$7.75 Million |
|
JW Pharmaceutical Corp
KO:001067
|
$7.75 Million |
|
Nelson Resources Ltd
AU:NES
|
$7.75 Million |
|
Openlearning Ltd
AU:OLL
|
$7.75 Million |
|
PLENUM AG NA O.N.
F:PLEK
|
$7.74 Million |
|
PLAYWITH Inc
KQ:023770
|
$7.73 Million |
|
Discoverie Group PLC
LSE:DSCV
|
$7.73 Million |
|
Encres Dubuit SA
PA:ALDUB
|
$7.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bergenbio ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 127,476,000 to 122,702,000, a change of -4,774,000 (-3.7%).
- Net loss of 139,282,000 reduced equity.
- Share repurchases of 138,874,000 reduced equity.
- New share issuances of 138,874,000 increased equity.
- Other factors increased equity by 134,508,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-139.28 Million | -113.51% |
| Share Repurchases | Nkr138.87 Million | -113.18% |
| Share Issuances | Nkr138.87 Million | +113.18% |
| Other Changes | Nkr134.51 Million | +109.62% |
| Total Change | Nkr- | -3.75% |
Book Value vs Market Value Analysis
This analysis compares Bergenbio ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Nkr2.44 | Nkr0.47 | x |
| 2015-12-31 | Nkr1.30 | Nkr0.47 | x |
| 2016-12-31 | Nkr3.03 | Nkr0.47 | x |
| 2017-12-31 | Nkr7.57 | Nkr0.47 | x |
| 2018-12-31 | Nkr6.22 | Nkr0.47 | x |
| 2019-12-31 | Nkr3.74 | Nkr0.47 | x |
| 2020-12-31 | Nkr8.95 | Nkr0.47 | x |
| 2021-12-31 | Nkr4.37 | Nkr0.47 | x |
| 2022-12-31 | Nkr0.11 | Nkr0.47 | x |
| 2023-12-31 | Nkr4.74 | Nkr0.47 | x |
| 2024-12-31 | Nkr3.14 | Nkr0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bergenbio ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -113.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16424.76%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.27x
- Recent ROE (-113.51%) is below the historical average (-106.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -47.51% | -9662.21% | 0.00x | 1.12x | Nkr-69.94 Million |
| 2015 | -111.37% | 0.00% | 0.00x | 1.27x | Nkr-78.58 Million |
| 2016 | -84.69% | 0.00% | 0.00x | 1.14x | Nkr-145.13 Million |
| 2017 | -52.01% | 0.00% | 0.00x | 1.10x | Nkr-217.24 Million |
| 2018 | -56.85% | -8211.86% | 0.01x | 1.12x | Nkr-225.47 Million |
| 2019 | -90.68% | -2239.08% | 0.03x | 1.23x | Nkr-221.25 Million |
| 2020 | -38.35% | -42766.89% | 0.00x | 1.10x | Nkr-324.05 Million |
| 2021 | -80.47% | -39969.51% | 0.00x | 1.17x | Nkr-347.81 Million |
| 2022 | -341.39% | -77666.32% | 0.00x | 1.88x | Nkr-310.97 Million |
| 2023 | -149.36% | -53785.59% | 0.00x | 1.37x | Nkr-203.15 Million |
| 2024 | -113.51% | -16424.76% | 0.01x | 1.27x | Nkr-151.55 Million |
Industry Comparison
This section compares Bergenbio ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $109,071,705
- Average return on equity (ROE) among peers: -109.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bergenbio ASA (BGBIO) | Nkr67.00 Million | -47.51% | 0.29x | $7.75 Million |
| Arcticzymes Technologies ASA (AZT) | $61.15 Million | -162.49% | 0.51x | $117.69 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $146.68 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $9.59 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $80.92 Million |
| Nykode Therapeutics ASA (NYKD) | $242.56 Million | -49.57% | 0.21x | $110.82 Million |
| Oncoinvent ASA (ONCIN) | $146.33 Million | -105.98% | 0.40x | $23.00 Million |
| PCI Biotech Holding ASA (PCIB) | $339.95 Million | -10.23% | 0.05x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $76.22 Million | -49.08% | 0.15x | $28.83 Million |
| Thor Medical ASA (TRMED) | $63.84 Million | -487.52% | 0.72x | $164.94 Million |
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.